Medical Marijuana, Inc.

Medical Marijuana, Inc. Subsidiary Kannaway® Celebrates Recent Federal Court Ruling on Delta-8 THC; Launches New Hemp Products

Retrieved on: 
Tuesday, May 31, 2022
Gummy candy, United States Court of Appeals for the Ninth Circuit, Disease, 2018 United States farm bill, CBD, CNBC, Food, Medical cannabis, News, OTC, The O.C., Medical Marijuana, Inc., Nature, Marketing, SAN, Securities Act of 1933, Securities Exchange Act of 1934, Industry, Safe harbor, Safety, Food and Drug Administration, Drug Quality and Security Act, Ninth, Sale, THC, United States farm bill, CA, GLOBE, Drug, Animal

Circuit Court of Appeals for deeming Delta-8 THC, a compound found in hemp, to be federally legal under the 2018 Farm Bill.

Key Points: 
  • Circuit Court of Appeals for deeming Delta-8 THC, a compound found in hemp, to be federally legal under the 2018 Farm Bill.
  • According to The Brightfield Group , social listening data shows online conversations about Delta-8 grew 163% from December 2020 to April 2021.
  • Kannaway is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Launches Pharma Subsidiary in Brazil; Expands Access to CBD Products in Pharmacies

Retrieved on: 
Thursday, May 26, 2022
Disease, CNBC, Food, Medical cannabis, OTC, The O.C., Medical Marijuana, Inc., Nature, Pharmacy, Cannabidiol, SAN, Securities Exchange Act of 1934, Securities Act of 1933, Â, Safe harbor, Safety, Food and Drug Administration, Drug Quality and Security Act, Sale, Growth, CA, GLOBE, Drug, Generic drug, CBD, Brazilian Health Regulatory Agency

Not only will our products be more affordable than other CBD products sold at drugstores in Brazil, but they will be of the highest quality.

Key Points: 
  • Not only will our products be more affordable than other CBD products sold at drugstores in Brazil, but they will be of the highest quality.
  • In Brazil, CBD is currently permitted only for medical use with authorization from the countrys National Sanitary Surveillance Agency (Anvisa).
  • HM Pharma will operate under Anvisa Normative 327/2019 which allows the company to sell its products in pharmacies.
  • Medical Marijuana, Inc. subsidiary HempMeds Brasil was the first company to legally import products to Brazil in 2015 utilizing Brazils Compassionate Use laws.

Medical Marijuana, Inc. Subsidiary HempMeds Brasil Celebrates Feature in Forbes

Retrieved on: 
Monday, May 23, 2022
Steps, Disease, CNBC, Food, Â, Medical cannabis, OTC, Health, The O.C., Medical Marijuana, Inc., Nature, Epilepsy, Cannabidiol, SAN, Securities Exchange Act of 1934, Securities Act of 1933, Parkinson's disease, Safe harbor, Multiple sclerosis, Safety, Criticism of the Food and Drug Administration, Chronic pain, Drug Quality and Security Act, Attention, CA, GLOBE, Drug, CBD, Forbes, Brazilian Health Regulatory Agency, Cannabis

It is also important to note that in the first quarter of 2022, HempMeds Brasil grew 75.8% faster than the overall cannabidiol (CBD) market.

Key Points: 
  • It is also important to note that in the first quarter of 2022, HempMeds Brasil grew 75.8% faster than the overall cannabidiol (CBD) market.
  • This milestone can be attributed to the subsidiarys large network of doctors and medical professionals and the trustworthiness of its high-quality CBD products.
  • Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com .
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Reports $7.8 Million in Net Revenue in 2022 First Quarter Financial and Operational Results

Retrieved on: 
Thursday, May 19, 2022
Education, Company, Disease, CBD, CNBC, Food, Family, Medical cannabis, Duane syndrome, OTC, The O.C., Medical Marijuana, Inc., Nature, Research, SAN, Securities Act of 1933, Securities Exchange Act of 1934, Safe harbor, Safety, Food and Drug Administration, Drug Quality and Security Act, CA, GLOBE, Drug, Online gambling, Inc.

The opportunity for our family of companies has never been greater and I remain extremely optimistic about our positioning through 2022 and beyond, said Medical Marijuana, Inc. CEO Blake Schroeder.

Key Points: 
  • The opportunity for our family of companies has never been greater and I remain extremely optimistic about our positioning through 2022 and beyond, said Medical Marijuana, Inc. CEO Blake Schroeder.
  • Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com .
  • This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Subsidiary Kannaway® Announces Positive Preliminary Results of Validcare CBD Safety Study

Retrieved on: 
Wednesday, May 18, 2022
Disease, CBD, CNBC, Food, Â, Medical cannabis, Chief of Army Staff (Pakistan), Testosterone, OTC, The O.C., Medical Marijuana, Inc., Nature, FDA, Cannabidiol, SAN, Securities Exchange Act of 1934, Industry, Securities Act of 1933, CRO, Safe harbor, Safety, Criticism of the Food and Drug Administration, Drug Quality and Security Act, CA, CEO, GLOBE, Drug, Dietary supplement

Validcare acted as CRO for the study, which was completed on March 22, 2022, and involved 1,061 U.S. participants and 17 CBD companies, including Kannaway.

Key Points: 
  • Validcare acted as CRO for the study, which was completed on March 22, 2022, and involved 1,061 U.S. participants and 17 CBD companies, including Kannaway.
  • These new results will provide the FDA with the data needed to address its safety concerns regarding CBD.
  • We hope that these results, paired with the results from the first cohort of the study , will persuade the FDA to take steps to regulate CBD, said Blake Schroeder, CEO of Medical Marijuana, Inc. and Kannaway.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Celebrates Largest Revenue Month of 2022 in April, Japan Division Achieves Best Revenue Month in History of the Company

Retrieved on: 
Thursday, May 12, 2022
Company, Disease, CNBC, Research, Food, OTC, Medical cannabis, The O.C., Medical Marijuana, Inc., Nature, SAN, Securities Act of 1933, Securities Exchange Act of 1934, Safe harbor, Safety, Criticism of the Food and Drug Administration, Drug Quality and Security Act, Saudi Research and Marketing Group, Growth, CA, GLOBE, Drug, CBD

Specifically, the Asia-Pacific has been a major growth area for our Company and was a large contributor to our growth in April.

Key Points: 
  • Specifically, the Asia-Pacific has been a major growth area for our Company and was a large contributor to our growth in April.
  • We are connecting with new consumers in Japan daily and expect this trend to continue.
  • Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com .
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Subsidiary Kannaway® Welcomes Direct Sales Veteran Eric Glenn as Entrepreneur

Retrieved on: 
Wednesday, May 11, 2022
GLOBE, Company, Securities Exchange Act of 1934, CNBC, Securities Act of 1933, Safety, Food, CA, Food and Drug Administration, Medical Marijuana, Inc., OTC, Safe harbor, The O.C., Medical cannabis, Health, Marketing, Sale, Disease, CBD, SAN, Growth, Nature, Drug

His experience building multinational businesses gives me the utmost confidence in his ability to become a top producer for Kannaway.

Key Points: 
  • His experience building multinational businesses gives me the utmost confidence in his ability to become a top producer for Kannaway.
  • Eric Glenn is a direct selling veteran with 40 years of experience.
  • Kannaway is one the most trusted companies in the cannabis industry, and it is an honor to join this team, said Eric Glenn, Kannaway Entrepreneur.
  • Kannaway is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products.

Medical Marijuana, Inc. Honored as Silver Stevie Award Winner in the 2022 American Business Awards®

Retrieved on: 
Thursday, April 28, 2022
Safety, Stevie Awards, Securities Exchange Act of 1934, Safe harbor, Customer service, American Business Women's Association, GLOBE, Final good, United States House Foreign Affairs Subcommittee on the Middle East, North Africa and Global Counterterrorism, Organization, Food, Achievement, Growth, SAN, OTC, Securities Act of 1933, Company, Â, Food and Drug Administration, CBD, Workplace, CNBC, Medical cannabis, Nature, Industry, Drug Quality and Security Act, Woman, International business, CA, Disease, Medical Marijuana, Inc., The O.C., Drug, U.S.A

The American Business Awards are the U.S.A.s premier business awards program.

Key Points: 
  • The American Business Awards are the U.S.A.s premier business awards program.
  • Medical Marijuana, Inc. CEO Blake Schroeder received this award for his dedication to his colleagues, customers, and shareholders.
  • Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Celebrates Exponential Growth; Receives Validation From Medical Community

Retrieved on: 
Thursday, April 21, 2022
Alessandra Patelli, CNBC, Medical cannabis, Multiple sclerosis, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cannabidiol, Executive, The O.C., Safe harbor, Food, CA, GLOBE, OTC, Drug Quality and Security Act, Patient, SAN, Securities Exchange Act of 1934, Medical Marijuana, Inc., Growth, Company, Chronic pain, Cannabis, Criticism of the Food and Drug Administration, Safety, Parkinson's disease, Partnership, ANVISA, FDA, Industry, Epilepsy, Disease, University, Securities Act of 1933, Nature, Knowledge, Drug, Risk management, Pharmaceutical industry, CBD, Brazilian, Brazilian Health Regulatory Agency

In the first quarter of 2022, HempMeds Brasil grew at a rate 75.8% faster than the overall Brazilian CBD market.

Key Points: 
  • In the first quarter of 2022, HempMeds Brasil grew at a rate 75.8% faster than the overall Brazilian CBD market.
  • The Company foresees this trend to continue as HempMeds Brasil is well-positioned to capture market share and other industry players exit the market, resulting in an exciting growth market opportunity for HempMeds Brasil.
  • The course features four HempMeds representatives and is currently the most accessed piece of educational content on the platform.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Subsidiary Kannaway® Celebrates Best Revenue Month in Company History for South Africa Division in March 2022

Retrieved on: 
Thursday, April 14, 2022
CNBC, Market, Medical cannabis, Marketing, Safe harbor, The O.C., Food, CA, CAGR, GLOBE, Sale, OTC, Securities Act of 1933, SAN, Securities Exchange Act of 1934, Medical Marijuana, Inc., Growth, Criticism of the Food and Drug Administration, Safety, Disease, Nature, Drug, CBD

Reach and Markets highlights that the South African cannabis/cannabidiol (CBD) market is expected to see a CAGR of 28.4% Between 2022 and 2026 .

Key Points: 
  • Reach and Markets highlights that the South African cannabis/cannabidiol (CBD) market is expected to see a CAGR of 28.4% Between 2022 and 2026 .
  • 2022 has been a truly remarkable year for sales in South Africa so far, said Medical Marijuana, Inc. CEO Blake Schroeder.
  • Kannaway is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.